Evidence map›Paper›PMID 20807590›Full record

ReviewAutoimmunity reviews2010

Modulation of autoimmunity with artificial peptides.

Antonio La Cava

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Autoimmunity reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Antonio La CavaDivision of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA. alacava@mednet.ucla.edu
University of California, Los Angeles · US

Funding

Longitudinal changes in marrow fat, other fat depots and boneR01AR065645 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LI, XIAOJUAN, SCHWARTZ, ANN V · 2014 to 2017
$2.2M
Role of Leptin in Systemic Lupus ErythematosusR01AR053239 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LA CAVA, ANTONIO · 2006 to 2010
$1.6M
NIAMS NIH HHS AR65645NIAMS NIH HHS R01 AR053239NIAMS NIH HHS R01 AR065645
6 · The paper itself

Abstract

The loss of immune tolerance to self antigens leads to the development of autoimmune responses. Since self antigens are often multiple and/or their sequences may be known, one approach to restore immune tolerance uses synthetic artificial peptides that interfere or compete with self peptides in the networks of cellular interactions that drive the autoimmune process. This review describes the rationale behind the use of artificial peptides in autoimmunity and their mechanisms of action. Examples of use of artificial peptides in preclinical studies and in the management of human autoimmune diseases are provided.

Indexed as

AnimalsAutoimmune DiseasesAutoimmunityHumansImmune TolerancePeptidesPeptides

Identifiers

PMID20807590
PMCPMC2975760
OpenAlexW2032518161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.